Failure to Warn of Cancer Risk: Misny's Second Pharmaceutical Block Settles for $50 Million

In March 2009, the U.S. Supreme Court issued Wyeth v. Levine, ruling that FDA approval of a drug label does not insulate a manufacturer from state-law failure-to-warn claims. For personal-injury plaintiffs who had been held at bay by federal preemption arguments for years, the decision reshaped pharmaceutical litigation almost overnight.

Tim Misny had already been advertising nationally for clients who believed a prescription drug harmed them without adequate warning before the Wyeth opinion even came down. Within roughly a year of the ruling, he had assembled a large plaintiff group, close to 1,000 Ohioans in total across two separate pharmaceutical tort matters. One block of those cases, centered on a drug that failed to warn of elevated heart attack and stroke risk, settled in 2011 for $42.5 million. The second block involved a different drug whose manufacturer had not disclosed a materially increased risk of cancer on its label.

The failure-to-warn theory in the second matter tracked a well-established line of pharmaceutical liability law. Drug companies are required to communicate known material risks to prescribers and patients through labeling. When a company possessed internal data showing a meaningful association between its product and cancer but kept that information off the label, every patient who developed cancer while taking the drug and was never warned of the risk had a potential tort claim. Misny's role was to identify those Ohio clients, gather their medical and prescription records, and bring that plaintiff group into the coordinated proceeding where the broader case was litigated.

Serving as co-counsel in a coordinated pharmaceutical proceeding is a defined litigation posture: a firm contributes a substantial block of clients to a larger case led by other counsel, participates in discovery and settlement negotiations, and shares in the outcome proportionate to its plaintiff group. For Misny, bringing his Ohio cases into that consolidated effort gave those clients access to the resources and negotiating power of a coordinated proceeding that individual Ohio filings could not have achieved.

The second block settled in October 2012 for $50 million. News of the settlement reached Misny during a meeting that month, when a call from his co-counsel confirmed the figure, as recounted in a December 2012 Cleveland Magazine profile that reported both the amount and the timing. The drug involved and the corporate defendant were not publicly identified in available media coverage, which is common for confidential settlements within larger pharmaceutical cases. What the independent public record confirms is the $50 million figure, the October 2012 settlement date, and Misny's role as co-counsel; the firm characterizes the underlying claims as a cancer-labeling failure-to-warn matter.